GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OCSE:ZEAL) » Definitions » Enterprise Value

Zealand Pharma AS (OCSE:ZEAL) Enterprise Value : kr45,962.24 Mil (As of Dec. 12, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zealand Pharma AS's Enterprise Value is kr45,962.24 Mil. Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was kr-983.84 Mil. Therefore, Zealand Pharma AS's EV-to-EBIT ratio for today is -46.72.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Zealand Pharma AS's Enterprise Value is kr45,962.24 Mil. Zealand Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was kr-955.77 Mil. Therefore, Zealand Pharma AS's EV-to-EBITDA ratio for today is -48.09.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Zealand Pharma AS's Enterprise Value is kr45,962.24 Mil. Zealand Pharma AS's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was kr76.87 Mil. Therefore, Zealand Pharma AS's EV-to-Revenue ratio for today is 597.92.


Zealand Pharma AS Enterprise Value Historical Data

The historical data trend for Zealand Pharma AS's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Enterprise Value Chart

Zealand Pharma AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,238.64 7,652.37 5,629.91 9,632.09 20,272.84

Zealand Pharma AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16,361.82 20,272.84 40,837.00 54,755.49 49,353.26

Competitive Comparison of Zealand Pharma AS's Enterprise Value

For the Biotechnology subindustry, Zealand Pharma AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Enterprise Value falls into.



Zealand Pharma AS Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Zealand Pharma AS's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Zealand Pharma AS's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS  (OCSE:ZEAL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Zealand Pharma AS's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=45962.243/-983.843
=-46.72

Zealand Pharma AS's current Enterprise Value is kr45,962.24 Mil.
Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-983.84 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Zealand Pharma AS's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=45962.243/-955.767
=-48.09

Zealand Pharma AS's current Enterprise Value is kr45,962.24 Mil.
Zealand Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-955.77 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Zealand Pharma AS's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=45962.243/76.87
=597.92

Zealand Pharma AS's current Enterprise Value is kr45,962.24 Mil.
Zealand Pharma AS's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr76.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS Enterprise Value Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.